(Total Views: 666)
Posted On: 06/22/2019 4:11:13 AM
Post# of 30067
Coepits is in process of a capital raise to finish the acquisition.
AMBS Will end up owning about 50% of Coeptis.
http://www.wsw.com/webcast/ldmicro16/ambs/?lo...&day=2
What hasn't been discussed is how much cash up front AMBS will receive to close the deal.
ANI agreed to purchase seven development stage generic products from Coeptis Pharmaceuticals, Inc. for $2.3 million dollars in cash and up to $12.0 million ....
So, some cash infusions will be coming in over the next coyple of months.
And with Cutanogen and MANF still open for partnering or raising capital for stand alones.
And still the possible REG A+ on thw agenda.
It's a different year so people looking in the rearview mirror are missing the road signs right in front of them.
The raise for Todos also will fund a number of initiatives, one of which is...
"Complete ongoing confirmatory clinical trial for LymPro at Leipzig University"
Aloha
AMBS Will end up owning about 50% of Coeptis.
http://www.wsw.com/webcast/ldmicro16/ambs/?lo...&day=2
What hasn't been discussed is how much cash up front AMBS will receive to close the deal.
ANI agreed to purchase seven development stage generic products from Coeptis Pharmaceuticals, Inc. for $2.3 million dollars in cash and up to $12.0 million ....
So, some cash infusions will be coming in over the next coyple of months.
And with Cutanogen and MANF still open for partnering or raising capital for stand alones.
And still the possible REG A+ on thw agenda.
It's a different year so people looking in the rearview mirror are missing the road signs right in front of them.
The raise for Todos also will fund a number of initiatives, one of which is...
"Complete ongoing confirmatory clinical trial for LymPro at Leipzig University"
Aloha
(4)
(0)
